The Impact of Azacitidine and Venetoclax Versus Intensive Chemotherapy Induction on Outcomes after Allogeneic Stem-Cell Transplantation for Newly Diagnosed Acute Myeloid Leukemia.
Key Points
Azacitidine and venetoclax show promising outcomes compared to intensive chemotherapy in acute myeloid leukemia patients.
Overall survival rates were significantly improved with azacitidine and venetoclax versus conventional chemotherapy.
Assessment of treatment outcomes involved a cohort of patients newly diagnosed with acute myeloid leukemia.
These findings highlight the need for evolving therapeutic approaches to enhance survival in this high-risk population.
أثر الأزاسيتيدين والفينيتوكلوكس مقابل تحفيز العلاج الكيميائي المكثف على النتائج بعد زراعة الخلايا الجذعية المانحة لمرضى اللوكيميا النخاعية الحادة المُشخصين حديثًا. | Synapse